Association between neutropenia and survival to nab-paclitaxel and gemcitabine in patients with metastatic pancreatic cancer

zu Verbundenen Objekten

Standort
Deutsche Nationalbibliothek Frankfurt am Main
ISSN
2045-2322
Umfang
Online-Ressource
Sprache
Englisch
Anmerkungen
online resource.

Erschienen in
Association between neutropenia and survival to nab-paclitaxel and gemcitabine in patients with metastatic pancreatic cancer ; volume:10 ; number:1 ; day:6 ; month:11 ; year:2020 ; pages:1-8 ; date:12.2020
Scientific reports ; 10, Heft 1 (6.11.2020), 1-8, 12.2020

Urheber
Roviello, Giandomenico
Ramello, Monica
Catalano, Martina
D’Angelo, Alberto
Conca, Raffaele
Gasperoni, Silvia
Dreoni, Lorenzo
Petrioli, Roberto
Ianza, Anna
Nobili, Stefania
Aieta, Michele
Mini, Enrico
Beteiligte Personen und Organisationen
SpringerLink (Online service)

DOI
10.1038/s41598-020-76465-9
URN
urn:nbn:de:101:1-2020121520524856228152
Rechteinformation
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Letzte Aktualisierung
15.08.2025, 07:36 MESZ

Datenpartner

Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Original beim Datenpartner anzeigen

Beteiligte

  • Roviello, Giandomenico
  • Ramello, Monica
  • Catalano, Martina
  • D’Angelo, Alberto
  • Conca, Raffaele
  • Gasperoni, Silvia
  • Dreoni, Lorenzo
  • Petrioli, Roberto
  • Ianza, Anna
  • Nobili, Stefania
  • Aieta, Michele
  • Mini, Enrico
  • SpringerLink (Online service)

Ähnliche Objekte (12)

Pankreaskarzinom nab-Paclitaxel

Pankreaskarzinom nab-Paclitaxel

Breast cancer nab-Paclitaxel

Breast cancer nab-Paclitaxel

Nab-paclitaxel and gemcitabine plus camrelizumab and radiotherapy versus nab-paclitaxel and gemcitabine alone for locally advanced pancreatic adenocarcinoma: a prospective cohort study

Nab-paclitaxel and gemcitabine plus camrelizumab and radiotherapy versus nab-paclitaxel and gemcitabine alone for locally advanced pancreatic adenocarcinoma: a prospective cohort study

Sulindac (K-80003) with nab-paclitaxel and gemcitabine overcomes drug-resistant pancreatic cancer

Sulindac (K-80003) with nab-paclitaxel and gemcitabine overcomes drug-resistant pancreatic cancer

Nab-Paclitaxel beim NSCLC : therapeutischer Stellenwert von Nab-Paclitaxel in der Therapie des nicht kleinzelligen Lungenkarzinoms (NSCLC)

Nab-Paclitaxel beim NSCLC : therapeutischer Stellenwert von Nab-Paclitaxel in der Therapie des nicht kleinzelligen Lungenkarzinoms (NSCLC)

Necrosis of Pedunculated Lipofibroma by Nab-Paclitaxel

Necrosis of Pedunculated Lipofibroma by Nab-Paclitaxel

Real world evidence on gemcitabine and nab-paclitaxel combination chemotherapy in advanced pancreatic cancer

Real world evidence on gemcitabine and nab-paclitaxel combination chemotherapy in advanced pancreatic cancer

Leptomeningeal Carcinomatosis in a Patient with Pancreatic Cancer Responding to Nab-Paclitaxel plus Gemcitabine

Leptomeningeal Carcinomatosis in a Patient with Pancreatic Cancer Responding to Nab-Paclitaxel plus Gemcitabine

NAB-paclitaxel and gemcitabine in metastatic pancreatic ductal adenocarcinoma (PDAC): from clinical trials to clinical practice

NAB-paclitaxel and gemcitabine in metastatic pancreatic ductal adenocarcinoma (PDAC): from clinical trials to clinical practice

Neoadjuvant nab-paclitaxel in the treatment of breast cancer

Neoadjuvant nab-paclitaxel in the treatment of breast cancer

Modified FOLFIRINOX as a second-line therapy following gemcitabine plus nab-paclitaxel therapy in metastatic pancreatic cancer

Modified FOLFIRINOX as a second-line therapy following gemcitabine plus nab-paclitaxel therapy in metastatic pancreatic cancer

Cisplatin shows greater efficacy than gemcitabine when combined with nab-paclitaxel in metastatic triple-negative breast cancer

Cisplatin shows greater efficacy than gemcitabine when combined with nab-paclitaxel in metastatic triple-negative breast cancer

Verbundene Objekte